Core Points - Upstream Bio is hosting a conference call to discuss the Phase II VIBRANT top-line results of their lead asset, Verekitug [1][4] - The call includes forward-looking statements regarding the company's expectations and beliefs about future events [2] - Comparisons of Verekitug against existing treatments are based on third-party published data, with caution advised due to differences in trial designs and patient characteristics [3] Company Overview - Upstream Bio's CEO, Dr. Rand Sutherland, and Chief Medical Officer, Dr. Aaron Deykin, are present to discuss the results and future plans for Verekitug [4] - The agenda includes an overview of the results and a detailed review of the Phase II VIBRANT clinical study top-line results [4]

Core Insights - Upstream Bio, Inc. announced positive top-line results from the Phase 2 VIBRANT trial for verekitug, demonstrating significant efficacy in treating chronic rhinosinusitis with nasal polyps (CRSwNP) [1][6][12] Study Results - The VIBRANT trial met its primary endpoint with a statistically significant placebo-adjusted reduction in endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) at Week 24 [1][4] - Key secondary endpoints showed a reduction in nasal congestion score (NCS) by -0.8 (p=0.0003) and a 76% reduction (p=0.03) in the need for surgery or systemic corticosteroids [1][2][5] - The trial involved 81 adults and was designed as a global, randomized, double-blind, placebo-controlled study over 24 weeks [3][12] Safety Profile - Verekitug was generally well tolerated, with no serious adverse events (SAEs) reported, consistent with previous studies [1][5][6] Mechanism and Potential - Verekitug is a monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor, which is unique in its mechanism of action compared to existing therapies [1][13][18] - The results suggest that verekitug could advance the standard of care for CRSwNP and may have potential applications in other respiratory diseases, including severe asthma [6][7][18] Future Plans - Upstream Bio plans to engage with global regulatory authorities for further development and potential product approval of verekitug [7][12] - The company will present additional details from the VIBRANT trial at an upcoming medical conference [8]